Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430924
Status:
COMPLETED
Last Update Posted:
2012-02-08
First Post:
2007-02-01
Brief Title:
Inhibition of Aldosterone in Patients With Chronic Renal Disease
Sponsor:
Lene Boesby
Organization:
Herlev Hospital
Study Overview
Official Title:
The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine The hypothesis is that if loss of protein is lowered progression of renal disease with be slower than otherwise expected
Detailed Description:
Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy It is accepted that proteinuria is a surrogate measurement for progression If proteinuria can be lowered we hope to prolong patients pre-dialysis phase Our theory is that aldosterone inhibition will lead to this
For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without Blood pressures will be kept at the same level using other drugs
For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without Blood pressures will be kept at the same level using other drugs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-004411-21 | None | None | None |